Abstract
The diagnosis of ductal carcinoma in situ (DCIS) has increased dramatically following the widespread adoption of screening mammography. DCIS has a favorable prognosis overall, but is associated with an increased risk of invasive breast cancer (IBC) and occasionally, with poor outcomes. The goal of the multidisciplinary treatment of DCIS is to prevent the development of invasive disease. The identification of patients at elevated risk for progression or recurrence who require more aggressive multimodality therapy and, conversely, those who can safely forgo elements of the current therapeutic armamentarium are important current challenges.
Keywords: Ductal Carcinoma in Situ, DCIS, Controversies, Clinical Trials
Current Cancer Therapy Reviews
Title:Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies
Volume: 8 Issue: 3
Author(s): Robert E. Roses and Henry M. Kuerer
Affiliation:
Keywords: Ductal Carcinoma in Situ, DCIS, Controversies, Clinical Trials
Abstract: The diagnosis of ductal carcinoma in situ (DCIS) has increased dramatically following the widespread adoption of screening mammography. DCIS has a favorable prognosis overall, but is associated with an increased risk of invasive breast cancer (IBC) and occasionally, with poor outcomes. The goal of the multidisciplinary treatment of DCIS is to prevent the development of invasive disease. The identification of patients at elevated risk for progression or recurrence who require more aggressive multimodality therapy and, conversely, those who can safely forgo elements of the current therapeutic armamentarium are important current challenges.
Export Options
About this article
Cite this article as:
E. Roses Robert and M. Kuerer Henry, Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies, Current Cancer Therapy Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339412802653173
DOI https://dx.doi.org/10.2174/157339412802653173 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug-Resistant Epilepsy and Surgery
Current Neuropharmacology Tetrazole Derivatives as Promising Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Protein & Peptide Letters Novel Therapeutic Strategies For Angiogenesis Inhibition In Recurrent Ovarian Cancer
Current Angiogenesis (Discontinued) Cellular Senescence and Anti-Cancer Therapy
Current Drug Targets Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers
Current Medicinal Chemistry Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Current Medicinal Chemistry Transport Mechanism-Based Drug Molecular Design: Novel Camptothecin Analogues to Circumvent ABCG2-associated Drug Resistance of Human Tumor Cells
Current Pharmaceutical Design QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design Recent Advancemnts in Biodegradable Ocular Implants
Current Drug Delivery Osteoimmunology and Beyond
Current Medicinal Chemistry Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene
Current Drug Targets Pharmacogenetics of Drug Transporters
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry